Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
22 May 2020Website:
http://www.inarimedical.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 49 min agoDividend
Analysts recommendations
Institutional Ownership
NARI Latest News
Primary endpoint win driven by both hard clinical outcomes and hospital resource utilization Primary endpoint win driven by both hard clinical outcomes and hospital resource utilization
NARI's third-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
Inari Medical, Inc. (NASDAQ:NARI ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Marissa Bych - VP, IR Drew Hykes - President and CEO Kevin Strange - CFO Tom Tu - Chief Medical Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG David Rescott - Baird Chris Pasquale - Nephron Research Stephanie Piazzola - Bank of America Lei Huang - Wells Fargo Zachary Day - Canaccord Genuity Michael Sarcone - Jefferies Ravi Misra - Truist Securities Matthew Blackman - Stifel Operator Good day, and welcome to the Inari Medical Third Quarter 2024 Earnings Call. [Operator Instructions] Also, please be aware that today's call is being recorded.
Inari Medical, Inc. (NARI) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.05 per share a year ago.
IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024.
ALISO VIEJO, Calif. , Oct. 21, 2024 /PRNewswire/ -- Okami Medical today announced the closing of a $32.5M financing led by new investor Vensana Capital and joined by existing investors including U.S. Venture Partners, members of Okami's board of directors, and other medical device industry veterans.
Inari Medical (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will host an analyst and investor meeting to discuss the PEERLESS study following its presentation at the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The analyst and investor meeting will be held on Tuesday, October 29, 2024 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time.
IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Shares of Inari Medical Inc (NARI, Financial) surged 3.22% in mid-day trading on Oct 2. The stock reached an intraday high of $42.21, before settling at $41.94, up from its previous close of $40.63.
What type of business is Inari Medical?
Inari Medical is a company that manufactures specialized medical equipment for minimally invasive treatment of patients suffering from venous diseases. It was founded in 2011 and is headquartered in Irvine, California. The company began its direct commercial activities in 2017 after the approval by the US Food and Drug Administration (FDA) of its first two devices: - ClotTriever for the treatment of deep vein thrombosis. - FlowTriever for the treatment of pulmonary embolism and clots in the right atrium.
What sector is Inari Medical in?
Inari Medical is in the Healthcare sector
What industry is Inari Medical in?
Inari Medical is in the Medical Devices industry
What country is Inari Medical from?
Inari Medical is headquartered in United States
When did Inari Medical go public?
Inari Medical initial public offering (IPO) was on 22 May 2020
What is Inari Medical website?
https://www.inarimedical.com
Is Inari Medical in the S&P 500?
No, Inari Medical is not included in the S&P 500 index
Is Inari Medical in the NASDAQ 100?
No, Inari Medical is not included in the NASDAQ 100 index
Is Inari Medical in the Dow Jones?
No, Inari Medical is not included in the Dow Jones index
When was Inari Medical the previous earnings report?
No data
When does Inari Medical earnings report?
The next expected earnings date for Inari Medical is 28 February 2025